Investigation and Development of New Therapeutic Avenues for Scleroderma
Investigation and Development of New Therapeutic Avenues for Scleroderma
批准号:
8147047
负责人:
Emanual M. Maverakis
金额:
$230.88万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-30 至 2016-06-30
关键词:
AffinityAutoimmune DiseasesAutoimmunityBeliefBindingCellsCommon ColdDevelopmentDiseaseImmuneImmune responseImmune systemImmunosuppressive AgentsInfectionInvestigationLibrariesLigandsMediatingOrganPathway interactionsPatientsPharmaceutical PreparationsPlayPopulationPublishingRefractoryRoleSclerodermaScreening procedureSystemic SclerodermaT-Cell ActivationT-LymphocyteTechniquesTechnologyTherapeuticTherapeutic immunosuppressionTissuesabstractingbasecombinatorialdesigneffective therapyfightingimprovedinhibitor/antagonistnew therapeutic targetnovelnovel therapeuticspublic health relevanceskin disordersmall molecule
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Provided by the applicant)
Abstract: Currently there is no effective treatment for Scleroderma (systemic sclerosis), an autoimmune disease unresponsive to immunosuppressive therapy. This proposal is based upon the belief that two main barriers exist towards the cure of this disease. First, there is no published technology for isolating unmanipulated pathogenic T cells from patients with autoimmunity. Second, current immunosuppressive medications do not target the correct immune cells in these patients. In order to improve the treatment and survival of these patients it is critical to: identify the role that the immune system plays in this disease, determine the effect that current immunosuppressive therapies have on the patients' autoreactive immune response, identify new therapeutic targets by fully characterizing the autoreactive immune response in scleroderma, and finally to design novel inhibitors to these targets. Our specific hypothesis is that unmanipulated self- reactive T cell clones isolated directly from patients with scleroderma can be used to identify novel therapeutic targets and small molecules capable of selectively binding these pathogenic cells. This hypothesis is based upon the following observations. 1) We have developed a technique to directly isolate pure populations of clonally expanded T cells from patients with autoimmunity. 2) A high affinity ligand for a subpopulation of activated T cells was identified through a combinatorial screening approach. 3) Screening combinatorial libraries has identified inhibitors of key intracellular pathway required for T cell activation. Based upon these observations the experimental focus of this proposal will be to combinatorial libraries to identify novel T cell-inhibiting small molecules and T cell-specific ligands in an attempt to develop a highly effective therapeutic that can target and destroy pathogenic T cells in the setting of scleroderma and other immune mediated diseases of the skin.
Public Health Relevance: Normally the immune system functions to fight off infections such as the common cold. In patients with autoimmunity the cells of the immune system damage the tissues and organs of a patient. Some autoimmune diseases respond to immunosuppressive therapy while others are very refractory to treatment. Scleroderma is an autoimmune disease that does not respond to therapy. We will study the immune cells isolated from patients with scleroderma and attempt to identify new therapeutic targets for medications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Stratedigm S100EON high-parameter flow cytometer to support multi-institutional research programs
-
批准号:10431674
-
项目类别:
-
资助金额:$59.98万
-
财政年份:2022
-
负责人:Emanual M. Maverakis
-
依托单位:
Mentoring Translational Scientists in Clinical Trial Immune Monitoring
-
批准号:10359792
-
项目类别:
-
资助金额:$18.77万
-
财政年份:2021
-
负责人:Emanual M. Maverakis
-
依托单位:
Mentoring Translational Scientists in Clinical Trial Immune Monitoring
-
批准号:10670051
-
项目类别:
-
资助金额:$18.77万
-
财政年份:2021
-
负责人:Emanual M. Maverakis
-
依托单位:
Investigation and Development of New Therapeutic Avenues for Scleroderma
-
批准号:8792820
-
项目类别:
-
资助金额:$51.03万
-
财政年份:2011
-
负责人:Emanual M. Maverakis
-
依托单位:
Characterization of Pathogenic T cells in Alopecia Areata
-
批准号:8213547
-
项目类别:
-
资助金额:$7.38万
-
财政年份:2010
-
负责人:Emanual M. Maverakis
-
依托单位:
Characterization of Pathogenic T cells in Alopecia Areata
-
批准号:7880365
-
项目类别:
-
资助金额:$7.65万
-
财政年份:2010
-
负责人:Emanual M. Maverakis
-
依托单位:
Characterization of Pathogenic T cells in Alopecia Areata
-
批准号:8045448
-
项目类别:
-
资助金额:$7.36万
-
财政年份:2010
-
负责人:Emanual M. Maverakis
-
依托单位:
gC399tr an inhibitor of autoimmunity
-
批准号:7476622
-
项目类别:
-
资助金额:$11.37万
-
财政年份:2008
-
负责人:Emanual M. Maverakis
-
依托单位:
gC399tr an inhibitor of autoimmunity
-
批准号:7569013
-
项目类别:
-
资助金额:$11.63万
-
财政年份:2008
-
负责人:Emanual M. Maverakis
-
依托单位:
gC399tr an inhibitor of autoimmunity
-
批准号:7779385
-
项目类别:
-
资助金额:$11.9万
-
财政年份:2008
-
负责人:Emanual M. Maverakis
-
依托单位:
国内基金
海外基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
-
批准号:31171277
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:Christine Nardini
-
依托单位: